glp-1 and kidney function receptor agonists are increasingly used to treat type 2 diabetes obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal GLP-1 receptor agonists and next-generation

Considering the wide use of GLP-1RAs, it is essential to evaluate their potential efficacy and risks systematically

ACSL4: acyl-CoA synthetase long-chain family member 4

Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets

Most protocols follow a pattern like: Start at a low dose Increase every few weeks if you are tolerating it well Adjust pace based on side effects and progress Some people feel appetite changes within the first 12 weeks, but meaningful weight change typically builds over time

Antiinflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL12 and upregulation of IL10 production